|Year : 2020 | Volume
| Issue : 4 | Page : 153-156
Prostate cancer therapies and fertility: What do we really know?
Panagiotis Mourmouris1, Lazaros Tzelves1, Titos Deverakis1, Lazaros Lazarou1, Kimon Tsirkas1, Anastasia Fotsali2, Christiana Roidi2, Ioannis Varkarakis1
1 2nd Department of Urology, Sismanogleio General Hospital, National and Kapodistrian University of Athens, Athens, Greece
2 2nd nd Deparment of Urology, Athens Medical School, National and Kapodistrian University of Athens, Sismanogleio General Hospital, Athens, Greece
|Date of Submission||05-Mar-2021|
|Date of Decision||14-Mar-2021|
|Date of Acceptance||24-Mar-2021|
|Date of Web Publication||13-Aug-2021|
2nd Department of Urology, Sismanogleio General Hospital, National and Kapodistrian University of Athens, 1st Sismanogleiou Str, Marousi 15125, Athens
Source of Support: None, Conflict of Interest: None
We reviewed the literature for articles in English in the Medline database from 1970 until today. The keywords used were “prostate cancer,” “fertility,” “radical prostatectomy,” “external beam radiotherapy,” “androgen deprivation therapy,” and “chemotherapy.” Only the studies with full paper were included in our review. The knowledge for this important issue is minimal and more minimal tends to be the consent of the patients. Prostate cancer does not seem to directly influence fertility, but all its therapies directly or indirectly seem to do so. In many of them, the impact may be reversible, but the mechanisms of this impact are still under consideration. Prostate cancer treatments, predominantly radiation, can cause long-term azoospermia; however, the data in the literature are sparse, mainly derived from small series, and based on these, no safe conclusions can be drawn.
Keywords: Androgen deprivation therapy, chemotherapy, infertility, prostate cancer, radical prostatectomy, radiotherapy
|How to cite this article:|
Mourmouris P, Tzelves L, Deverakis T, Lazarou L, Tsirkas K, Fotsali A, Roidi C, Varkarakis I. Prostate cancer therapies and fertility: What do we really know?. Hellenic Urology 2020;32:153-6
| Introduction|| |
According to the American Cancer Society, prostate cancer is the most popular cancer with rates up to 19% (except for skin cancer). The rates of the first diagnosis of prostate cancer in the age group of 35–44 and 45–54 are 0.5% and 9.2%, respectively. The above-mentioned statistic data in conjunction with the mean age of man childbirth (33 years) along with the fact that men tend to start thinking of having children even after 55 years (13.3%), transform the decision for prostate cancer management, in a significant one. In this study, we are reviewing literature about the impact of prostate cancer and its therapy in men fertility, in an effort to increase the 8.7% of informed consent of the patients, according to a very recent study, for fertility issues after prostate cancer therapy.
| Prostate Cancer and Infertility|| |
The most important parameter when informing the patient is whether prostate cancer itself can affect spermatogenesis and, as a result, lead to infertility before starting any treatment. In contrast to testicular cancer, which is extensively reported in the literature, the data on prostate cancer are few and not well documented. A recent analysis of 409 men cryopreserving 717 sperm samples showed that just 6% of them suffered from prostate cancer. These patients with an average sperm count of 83.5 × 106 and an average combined motion rate of 50.2% did not have any sperm disorder in their majority. The same results are reported in other relevant studies., Cancer can produce catastrophic physiological changes in the body, systematic disorders from mediated factors such as interleukins, tumor necrosis factors, and other factors, as well as organic stress produced by the secretion of various hormonal factors. All the above results in decreased sperm quality ending to infertility. However, it is important to emphasize that none of the above data have been specifically studied for prostate cancer. The above leads us to the conclusion that prostate cancer itself does not cause significant changes in sperm quality fact that must be included in the patient consent form before treatment.
| Radical Prostatectomy|| |
The first and obvious mechanism, influencing the fertility of the patient undergoing radical prostatectomy, is anatomical. During radical prostatectomy, ligation of the seminal ducts, removal of the prostate and the seminal vesicles takes place, and erectile dysfunction occurs as a direct complication, which causes loss of ejaculation and inability to fertilize. However, the above does not directly affect spermatogenesis and the patient theoretically remains fertile and capable of fertilization by other means like in vitro fertilization. However, questions are raised by researchers on the possible effect of prostate removal on the patient's hormonal profile and on whether this effect can negatively affect spermatogenesis. Miller et al. studying 63 men who underwent open radical prostatectomy, concluded that postsurgery showed an increase in serum total and free testosterone, oestradiol, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) while showing a decrease in dihydrotestosterone (DHT) (P < 0.0001). The researchers conclude that the prostate probably participates in a negative biofeedback mechanism with the hypothalamic–pituitary axis through substances that remain to be demonstrated. Similarly, a more recent study has shown that a statistically significant reduction of LH by 53% and DHT by 13% was observed in a 55-man sample, while FSH increased by 21% and inhibin B was also changed. The above studies, combined with even bigger, suggest a correlation of the hypothalamic–pituitary axis with the prostate as the main mechanism of disorder of the hormone profile of patients after radical prostatectomy. In this case, considering the fact that the values of inhibin B and FSH are directly related to spermatogenesis,, we conclude that radical prostatectomy itself may play a direct role in the infertility of patients.
| Radiation Therapy and Brachytherapy|| |
Testicles are extremely sensitive to radiation, especially the cells of the genital cord. Doses above 4 Gy can cause permanent damage to these cells. Instead, hypogonadism due to Leydig cell damage requires higher doses of radiation (20 Gy). However, radiation therapy for prostate cancer causes a rather negligible destruction of the testicular tissue, despite the fact that the latter receives a 3%–8% of the radiation dose.,, Surprisingly, there are many reports in the literature on clinically significant hypogonadism that persists for at least 2 years after radiotherapy for prostate cancer,,, while histological examination of testis samples taken for recurrent prostate cancer has revealed significant testicular atrophy.
Apart from the dose of radiation, there are other factors that affect the quality of the sperm. These include direct or indirect radiation, number and duration of dosages, and personalized factors such as the response of the patient's tissue to radiation and age. Doses between 0.35 and 0.5 Gy result in reversible azoospermia which is reversed after 10–18 months. However, if the dose rises above 1.2 Gy, then the risk of nonreturn to normal levels is greater.,, Clearly newer imaging and radiotherapy techniques can further reduce testicular radiation in an effort to maintain a patient's fertility. Finally, it is important not to neglect, the potential effects of brachytherapy for prostate cancer on the fertility of patients. Very few data are available in the literature; however, they support that after this therapy, the dose that testicles absorb is clearly negligible (<0.2Gy). A mild and mainly transient oligoasthenospermia may be observed in patients, however the authors suggest waiting from 4 to 12 months for a childbearing attempt.,
| Androgen Deprivation Therapy|| |
Hormonal manipulations succeed in controlling prostate cancer by suppressing testicular testosterone, but it leads to both oligoasthenospermia, loss of libido, and erectile function of patients, leading to infertility. However, most authors are focusing on the study of the potential return of testosterone and spermatogenesis after discontinuation of hormonal manipulation. The quality of the data available in the literature is low because most of them are small case series. In one of these, authors, following 14 patients under androgen blockade, studied the hormonal profile of patients after discontinuation of hormonal manipulation. The conclusion of this study is that although the return of the hypothalamic–pituitary–testicular axis was different among patients, the trend was for prolonged maintenance of low testosterone levels even for more than 1 year after hormone disruption. This low testosterone, following long-term administration of the Luteinizing hormone-releasing hormone (LHRH) agonist, may not stem from permanent suppression of the axis but from an irreversible destruction of Leydig cells. In contrast, a study of animal models revealed a potential reversal of fertility after discontinuation of a short-term hormone therapy.
| Chemotherapy|| |
The incidence of chemotherapeutic agents in fertility has been extensively studied for the most widely used agents and for the treatment of the most common neoplasms. In this context, it has been found that alkylating agents such as cyclophosphamide and iphosphamide are at high risk for prolonged azoospermia, while agents such as vincristine and methotrexate are rather low-risk therapies for infertility. However, there are no direct data on the potential for infertility after chemotherapy for prostate cancer, and this may be due to the fact that these patients may not be interested in becoming parents, so organize such a study would be difficult if not impossible. However, there is evidence from indirect studies using the chemotherapeutic agents that are also used in prostate cancer such the recent study by Chatzidarellis et al. who found a statistically significant reduction of inhibin B and FSH (P < 0.001 and P = 0.000, respectively) after taxane administration, which was maintained throughout the follow-up (6 months). Authors conclude that the above changes in combination with the observed bilateral decrease in testicular size indicate a significant gonadal damage following the administration of chemotherapeutic agents such as docetaxel. The results of the above study, if combined with the results of studies demonstrating the direct correlation of inhibin B values with spermatogenesis,, can lead to the indirect conclusion that chemotherapy for prostate cancer can cause infertility in patients receiving it.
| Conclusions|| |
As the age of the first diagnosis of prostate cancer decreases, the need for clear answers and solutions for the possible infertility that the treatments potentially cause will increase. Both prostate cancer itself and its treatments, predominantly radiation, can cause long-term azoospermia; however, the data in the literature are sparse, mainly derived from small series, and based on these, no safe conclusions can be drawn.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al
. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD. Available from: https://seer.cancer.gov/csr/1975_2014/
, based on November 2016 SEER data submission, posted to the SEER web site. [Last accessed on 2017 Apr 01].
Huyghe E, Sui D, Odensky E, Schover LR. Needs assessment survey to justify establishing a reproductive health clinic at a comprehensive cancer center. J Sex Med 2009;6:149-63.
Boyd BG, McCallum SW, Lewis RW, Terris MK. Assessment of patient concern and adequacy of informed consent regarding infertility resulting from prostate cancer treatment. Urology 2006;68:840-4.
Williams DH 4th
, Karpman E, Sander JC, Spiess PE, Pisters LL, Lipshultz LI. Pretreatment semen parameters in men with cancer. J Urol 2009;181:736-40.
Ragni G, Somigliana E, Restelli L, Salvi R, Arnoldi M, Paffoni A. Sperm banking and rate of assisted reproduction treatment: Insights from a 15-year cryopreservation program for male cancer patients. Cancer 2003;97:1624-9.
Meseguer M, Molina N, Garcia-Velasco JA, Remohi J, Pellicer A, Garrido N. Sperm cryopreservation in oncological patients: A 14-year follow-up study. Fertil Steril 2006;85:640.
Carroll PR, Whitmore WF Jr., Herr HW, Morse MJ, Sogani PC, Bajorunas D, et al
. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. J Urol 1987;137:420-3.
Meirow D, Schenker JG. Cancer and male infertility. Hum Reprod 1995;10:2017-22.
Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, et al
. Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449-53.
Olsson M, Ekström L, Schulze J, Kjellman A, Akre O, Rane A, et al
. Radical prostatectomy: Influence on serum and urinary androgen levels. Prostate 2010;70:200-5.
Bantis A, Zissimopoulos A, Athanasiadou P, Gonidi M, Agelonidou E, Strataki A, et al
. Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements. Hell J Nucl Med 2007;10:56-61.
Klingmüller D, Haidl G. Inhibin B in men with normal and disturbed spermatogenesis. Hum Reprod 1997;12:2376-8.
Andersson AM, Petersen J, Jorgensen N, Jensen TK, Skakkebaek NE. Serum inhibin B and follicle-stimulating hormone levels as tools in the evaluation of infertile men: Significance of adequate reference values from proven fertile men. J Clin Endocrinol Metab 2004;89:2873-9.
Zagars GK, Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;39:85-9.
Seal US. The Veterans Administration Uro-Oncology Research Group. Investigative Urol 1978;16:278-80.
Tomić R, Bergman B, Damber JE, Littbrand B, Löfroth PO. Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin. J Urol 1983;130:287-9.
Grigsby PW, Perez CA. The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate. J Urol 1986;135:726-7.
Fransson P, Widmark A. Self-assessed sexual function after pelvic irradiation for prostate carcinoma. Comparison with an age-matched control group. Cancer 1996;78:1066-78.
Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, et al
. Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study. J Clin Oncol 1998;16:275-83.
Fransson P, Widmark A. Late side effects unchanged 4±8 years after radiotherapy for prostate carcinoma: A comparison with age-matched controls. Cancer 1999;85:678-88.
Daniell HW. A worse prognosis for men with testicular atrophy at therapeutic orchiectomy for prostate carcinoma. Cancer 1998;83:1170-3.
Meistrich ML, Vassilopoulou-Sellin R, Lipshultz LI. Adverse effects of treatment: Gonadal dysfunction. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 7th
ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 2560-74.
Colpi GM, Contalbi GF, Nerva F, Sagone P, Piediferro G. Testicular function following chemo-radiotherapy. Eur J Obstet Gynecol Reprod Biol 2004;113 Suppl 1:S2-6.
Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr. 2005:12-7.
Wu Q, Liang J, Yan D. Application of dose compensation in image-guided radiotherapy of prostate cancer. Phys Med Biol 2006;51:1405-19.
Steinsvik EA, Fosså SD, Lilleby W, Eilertsen K. Fertility issues in patients with prostate cancer. BJU Int 2008;102:793-5.
Mydlo JH, Lebed B. Does brachytherapy of the prostate affect sperm quality and/or fertility in younger men? Scand J Urol Nephrol 2004;38:221-4.
Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999;53:898-902.
Pedraza R, Kwart AM. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: Is there a role for discontinuing treatment after prolonged androgen suppression? Urology 2003;61:770-3.
Kostanski JW, Jiang G, Dani BA, Murty SB, Qiu W, Schrier B, et al
. Return to fertility after extended chemical castration with a GnRH antagonist. BMC Cancer 2001;1:18.
Dohle GR. Male infertility in cancer patients: Review of the literature. Int J Urol 2010;17:327-31.
Chatzidarellis E, Makrilia N, Giza L, Georgiadis E, Alamara C, Syrigos KN. Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis. Fertil Steril 2010;94:558-63.
Kumanov P, Nandipati K, Tomova A, Agarwal A. Inhibin B is a better marker of spermatogenesis than other hormones in the evaluation of male factor infertility. Fertil Steril 2006;86:332-8.